Tislelizumab Medicine 04 June 2024 Extended indication Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Tislelizumab Domain Oncology Reason of inclusion Indication extension IND Main indication Lung cancer Extended indication Extension of indication to include treatment of adult patients with non-small cell lung cancer (NSCLC) in combination and as monotherapy Current proprietary name Already available biosimilars / generics Proprietary name Tevimbra Manufacturer BeiGene Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date April 2024 Expected Registration February 2025 Orphan drug Unknown Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks